...
MRKMEGA

Merck & Co., Inc.

HealthcareDrug Manufacturers - General
$123.78
$0.05(+3.74%)
52W$73.31
$125.14
FinancialsValuationvs PFE
Updated Feb 28, 12:00 AM
RSI56
RS Rating84/99
Beta0.43
Volatility29%
F-Score2/9
Mkt Cap$307.2B
STAGE 2 UPTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

STAGE 2 UPTREND

Merck & Co., Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings contraction of 20% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.

Relative Strength
84
out of 99
Market Leader
Trend Score
4/4
Minervini Criteria
STAGE 2 UPTREND
Risk (Beta)
0.43
vs S&P 500
LOW VOL
52W Position
97%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

STAGE 2 UPTREND4/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$112.30
50 SMA > 100 SMA$102.25
100 SMA > 150 SMA$95.82
150 SMA > 200 SMA$91.80

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$119.76+3.36%ABOVE
50 SMA$112.30+10.23%ABOVE
100 SMA$102.25+21.06%ABOVE
150 SMA$95.82+29.18%ABOVE
200 SMA$91.80+34.83%ABOVE

Price Performance

1D+3.7%
1W-0.0%
1M+15.8%
3M+18.1%
6M+48.8%
YTD+16.3%
1Y+34.2%
3Y+5.2%
52-Week Trading Range97% from low
$123.78
52W Low$73.31
52W High$125.14

Technical Indicators

RSI (14)NEUTRAL
56.0
305070
VCP ScoreHOT
8/10
Base depth: 23.5%

Risk Profile

Beta
0.43
52W Vol
29%
ATR
$2.96
Max DD (1Y)
-23%

Volume Analysis

Today
123
50D Avg
10.77M
Vol Ratio
0.00x
Liquidity
VERY LIQUID

Earnings Momentum

Q1'25+7%
$2.01
Q2'25-18%
$1.76
Q3'25+87%
$2.32
Q4'25-20%
$1.19
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+5.11%
5 Years:+9.38%
3 Years:+3.12%
TTM:+1.31%

Compounded Profit Growth

10 Years:+16.65%
5 Years:+21.23%
3 Years:+8.43%
TTM:+8.17%

Stock Price CAGR

10 Years:+9.96%
5 Years:+12.39%
3 Years:+5.23%
1 Year:+34.18%

Return on Equity

10Y Avg:25.5%
5Y Avg:30.8%
3Y Avg:26.3%
Last Year:35.2%

Key Metrics

Market Cap$307.2B
Gross Margin81.5%
Net Margin28.1%
Piotroski F-Score2/9

More MRK Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

MRK vs PFEPFEGSKSNYGRFS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 84 meansMRK outperformed 84% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.43 means 57% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 8/10 with HOT status.

Frequently Asked Questions

Is MRK in an uptrend right now?

MRK has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, MRK is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.

Is MRK overbought or oversold?

MRK's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.

Is MRK outperforming the market?

MRK has a Relative Strength (RS) Rating of 84 out of 99. Yes, MRK is a market leader, outperforming 84% of all stocks over the past 12 months.

Where is MRK in its 52-week range?

MRK is trading at $123.78, which is 99% of its 52-week high ($125.14) and 97% above its 52-week low ($73.31).

How volatile is MRK?

MRK has a Beta of 0.43 and 52-week volatility of 29%. It's less volatile than the S&P 500 - generally more stable.